Skip to main content
. Author manuscript; available in PMC: 2011 Sep 15.
Published in final edited form as: Bioorg Med Chem. 2010 Aug 1;18(18):6695–6700. doi: 10.1016/j.bmc.2010.07.061

Figure 3.

Figure 3

Effect of L-lysine co-injection on the tumor and kidney uptakes of 99mTc-RGD-Lys-(Arg11)CCMSH and 99mTc-RGD-Arg-(Arg11)CCMSH at 2 h post-injection. The white (□) and light grey (Inline graphic) columns represented the tumor and renal uptakes of 99mTc-RGD-Lys-(Arg11)CCMSH with or without L-lysine co-injection. The heavy grey (Inline graphic) and black (■) columns represented the tumor and renal uptakes of 99mTc-RGD-Arg-(Arg11)CCMSH with or without L-lysine co-injection. L-lysine co-injection significantly (*p<0.05) reduced the renal uptakes of 99mTc-RGD-Arg-(Arg11)CCMSH by 27.7% and 99mTc-RGD-Lys-(Arg11)CCMSH by 52.1% at 2 h post-injection without affecting the tumor uptakes. Meanwhile, the tumor uptake value of 99mTc-RGD-Arg-(Arg11)CCMSH was 1.44 times (*p<0.05) the tumor uptake value of 99mTc-RGD-Lys-(Arg11)CCMSH at 2 h post-injection.